The best reperfusion strategy for medium-sized vessel occlusion (MeVO) is not well established. Given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (LVO), the investigators hypothesized that intra-arterial tenecteplase (TNK) could increase the recanalization rate of MeVO and thus improve clinical outcome. The current study aimed to explore the safety and efficacy of intra-arterial TNK in patients with MeVO.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
80
intra-arterial tenecteplase
General Hospital of Northern Theater Command
Shenyang, China
proportion of patients with successful Medium vessel occlusion (MeVO) recanalization
successful MeVO recanalization is defined as the expanded treatment in cerebral ischemia (eTICI) score 2b67-3 in the territory of the target occluded MeVO artery
Time frame: immediately after finishing intra-arterial tenecteplase
proportion of modified Rankin Scale (mRS) 0-1
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: Day 90
proportion of modified Rankin Scale (mRS) 0-2
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: Day 90
distribution of modified Rankin Scale (mRS)
mRS scores range from 0 to 6, with higher scores indicating worse outcome
Time frame: Day 90
incidence of early neurological improvement
early neurological improvement is defined as a decrease of more than 4 points or reaching 0 points in NIHSS score, compared with baseline
Time frame: 24 (-6/+24) hours
Changes in National Institute of Health stroke scale (NIHSS)
NIHSS scores range 0-42, with higher scores indicating greater stroke severity
Time frame: 24 (-6/+24) hours
rate of visual recovery in patients with posterior cerebral artery occlusion
Time frame: 7 days or at hospital discharge
proportion of symptomatic intracranial hemorrhage
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
symptomatic intracranial hemorrhage is defined as an increase in the NIHSS score of ≥4 points as a result of the intracranial hemorrhage
Time frame: 24 (-6/+24) hours
proportion of parenchymal hematoma type 1 and 2
Time frame: 24 (-6/+24) hours
all serious adverse events
Time frame: 24 (-6/+24) hours
all-cause death
Time frame: 7 days
recurrent stroke, cardiovascular events, other vascular events and death
Time frame: 90 days